Janus Henderson Group PLC raised its stake in Novo Nordisk A/S (NYSE:NVO) by 11.4% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 247,811 shares of the company’s stock after buying an additional 25,382 shares during the period. Janus Henderson Group PLC’s holdings in Novo Nordisk A/S were worth $12,963,000 at the end of the most recent reporting period.
Other institutional investors also recently modified their holdings of the company. Boston Partners acquired a new position in Novo Nordisk A/S during the 4th quarter worth $99,963,000. Fisher Asset Management LLC raised its stake in Novo Nordisk A/S by 2.9% in the fourth quarter. Fisher Asset Management LLC now owns 14,202,935 shares of the company’s stock valued at $654,329,000 after purchasing an additional 405,531 shares in the last quarter. Avalon Advisors LLC raised its stake in Novo Nordisk A/S by 494.7% in the fourth quarter. Avalon Advisors LLC now owns 422,932 shares of the company’s stock valued at $19,484,000 after purchasing an additional 351,810 shares in the last quarter. Two Sigma Advisers LP raised its stake in Novo Nordisk A/S by 897.5% in the fourth quarter. Two Sigma Advisers LP now owns 278,300 shares of the company’s stock valued at $12,821,000 after purchasing an additional 250,400 shares in the last quarter. Finally, CIBC Asset Management Inc acquired a new position in Novo Nordisk A/S in the fourth quarter valued at about $11,418,000. 7.04% of the stock is owned by institutional investors.
Shares of NYSE NVO opened at $46.94 on Thursday. The company has a debt-to-equity ratio of 0.07, a current ratio of 0.96 and a quick ratio of 0.66. The stock has a market cap of $115.75 billion, a price-to-earnings ratio of 18.63, a price-to-earnings-growth ratio of 2.12 and a beta of 0.56. Novo Nordisk A/S has a 12 month low of $41.23 and a 12 month high of $52.83.
WARNING: This report was reported by Community Financial News and is the property of of Community Financial News. If you are accessing this report on another publication, it was illegally copied and republished in violation of international trademark & copyright laws. The original version of this report can be viewed at https://www.com-unik.info/2019/05/16/novo-nordisk-a-s-nvo-shares-bought-by-janus-henderson-group-plc.html.
Novo Nordisk A/S Profile
Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases.
See Also: What is Compound Interest?
Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.